Cagrilintide is in Phase III development (not yet approved). In a Phase II trial (706 patients), cagrilintide 4.5 mg achieved 10.8% weight loss, outperforming the active comparator liraglutide 3.0 ...
View full compound profile →Vendors stocking
5
across 5 countries
Total listings
5
4 in stock
Price range
$132.00
Median price per mg
$18.99
Most common size
5mg
3 listings
Stock health
80%
4 vendors · 4 listings
This compound is currently in clinical trials and is not yet approved for commercial sale. Information is for research reference only.
Prices last updated: 15 May 2026
Data sourced from 5 vendor websites across 5 countries
